Delta-fly pharma inc.: fda submission of the protocol of the phase i/ii study of dfp-10917 combined with venetoclax (vtx) in the aml patients pretreated by vtx involved one regimen

Tokushima, japan--(business wire)--following to the previous information on jan. 30th. in 2024, we are excited to share our latest development status. fda submission of the protocol of the phase i/ii study of dfp-10917 combined with venetoclax (vtx) in the aml patients pretreated by vtx involved one regimen have been done on march 8th, 2024. the phase i/ii study of dfp-10917 with vtx in the above aml patients shall be started at wake forest and the other hospitals soon after fda approval. the i.
DAL Ratings Summary
DAL Quant Ranking